2024年6月7日

TechDoctor, a digital biomarker developer, is the first Japanese startup company to participate in a project of the international Digital Medicine Society (DiMe) 

Building the Business Case for Digital Endpoints in Clinical Trials

—-----------------------------

TechDoctor, Inc. (CEO: Kazuhisa Minato, Head Office: Chuo-ku, Tokyo; hereinafter referred to as "TechDoctor") is pleased to announce that it will be the first Japanese startup company to participate in the "Building a Business Case for Digital Endpoints" project run by DiMe (the Digital Medicine Society). This project is designed to build a business case for digital endpoints, promoting the adoption of digital endpoints (digital metrics in clinical trials) to improve the accuracy and efficiency of research.

--------------------------------------------------------------------------------

About DiMe (Digital Medicine Society)

--------------------------------------------------------------------------------

DiMe (Digital Medicine Society) is a global non-profit organization founded in 2019, a community of professionals dedicated to the advancement of digital medicine.

FDA (Food and Drug Administration) and numerous researchers and companies participate in research, guideline development, education, and other activities.

https://dimesociety.org/

--------------------------------------------------------------------------------

Overview of the project, "Building the Business Case for Digital Endpoints"

--------------------------------------------------------------------------------

The project theme for TechDoctor's participation is "Building the Business Case for Digital Endpoints."

Under the U.S. Food and Drug Administration's Medical Device Development Tool (MDDT) program, digital endpoints were approved for the first time for clinical trials. This is a major step toward the use of digital metrics in clinical trials, which will advance the way outcomes are measured and increase the accuracy and efficiency of research.

This project aims to facilitate the development and utilization of digital endpoints in clinical trials by developing a value framework for digital endpoints, industry benchmarking tools, ROI forecasting models, and modular business case templates.

Building these business cases will clearly define the value of implementing digital endpoints and facilitate decision making.

--------------------------------------------------------------------------------

Challenges and Expectations in the Use of Digital Endpoints

--------------------------------------------------------------------------------

Digital endpoints can capture many insights from routine data of clinical trial participants and help to deepen our understanding of disease. By leveraging them, clinical trials can become more patient-centered, data-driven, and adaptable to the evolving needs of healthcare research.

DiMe, in collaboration with the Tufts Center for Drug Development and Research, Johnson & Johnson, Roche, Genentech, UCB, Bayer, Takeda, and MindMed, suggests that significant cost savings and financial benefits can be realized when using digital endpoints in clinical trials. The following are some suggestions.

While research on various digital endpoints is progressing, they have not yet become central to drug and medical device development because their clear value and efficient use have not yet been defined.

Through this project, we will establish a common industry value framework to help companies make decisions to invest in digital endpoints.

"Digital measures bring immense value to clinical research, but adopters often struggle to make the case for broader use," said Victoria Bangieva, PhD, Program Director within DiMe's Digital Measures and Diagnostics team. "At DiMe, we're committed to advancing the use of digital health measures in research to improve lives and value the partnership with groups like Tech Doctor to develop opensource resources that will help drive the industry towards increased utilization."

TechDoctor CEO Kazumichi Minato said, "we are proud to be the first Japanese start-up company to participate in the DiMe project and to be involved in the creation of global standards. We hope to build upon our work with digital biomarkers as endpoints in clinical research that will improve the accuracy and efficiency of drug and medical device research and development and lead to improved patient care worldwide."

DiMe Project Page:

https://datacc.dimesociety.org/building-the-business-case-for-digital-endpoints/